Evatanepag 是一种 EP2 受体选择性前列腺素 E2 (PGE2) 激动剂，可诱导局部骨形成，EC50 为 0.3 nM。它在大鼠骨折愈合模型中以单剂量局部给药时表现出愈合骨折的能力。

Evatanepag is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing.

CP-533536 is a potent and selective EP2agonist. CP-533536 shows the ability to heal fractures when administered locally as a single dose in rat models of fracture healing s excellent in vitro potency and it also displays against EP2 and selectivity against a broad panel of other targets.

223488-57-1

C25H28N2O5S

468.57

CP-533536 free acid;2-[3-[N-(4-叔丁基苄基)-N-(吡啶-3-基磺酰基)氨基甲基]苯氧基]乙酸

DMSO:32 mg/mL (68.29 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years